Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 54.40
SCLN's Cash to Debt is ranked higher than
79% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. SCLN: 54.40 )
SCLN' s 10-Year Cash to Debt Range
Min: 2.83   Max: No Debt
Current: 54.4

Equity to Asset 0.86
SCLN's Equity to Asset is ranked higher than
91% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. SCLN: 0.86 )
SCLN' s 10-Year Equity to Asset Range
Min: 0.52   Max: 0.95
Current: 0.86

0.52
0.95
Interest Coverage 101.25
SCLN's Interest Coverage is ranked higher than
66% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. SCLN: 101.25 )
SCLN' s 10-Year Interest Coverage Range
Min: 34.65   Max: 9999.99
Current: 101.25

34.65
9999.99
F-Score: 7
Z-Score: 7.11
M-Score: -2.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.21
SCLN's Operating margin (%) is ranked higher than
72% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. SCLN: 8.21 )
SCLN' s 10-Year Operating margin (%) Range
Min: -6000   Max: 26.31
Current: 8.21

-6000
26.31
Net-margin (%) 8.63
SCLN's Net-margin (%) is ranked higher than
77% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. SCLN: 8.63 )
SCLN' s 10-Year Net-margin (%) Range
Min: -4933.33   Max: 24.77
Current: 8.63

-4933.33
24.77
ROE (%) 7.48
SCLN's ROE (%) is ranked higher than
74% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SCLN: 7.48 )
SCLN' s 10-Year ROE (%) Range
Min: -293.06   Max: 25.65
Current: 7.48

-293.06
25.65
ROA (%) 6.08
SCLN's ROA (%) is ranked higher than
81% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. SCLN: 6.08 )
SCLN' s 10-Year ROA (%) Range
Min: -180.34   Max: 21.55
Current: 6.08

-180.34
21.55
ROC (Joel Greenblatt) (%) 39.33
SCLN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. SCLN: 39.33 )
SCLN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2257.14   Max: 96.28
Current: 39.33

-2257.14
96.28
Revenue Growth (%) 10.30
SCLN's Revenue Growth (%) is ranked higher than
76% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SCLN: 10.30 )
SCLN' s 10-Year Revenue Growth (%) Range
Min: -4.7   Max: 125.7
Current: 10.3

-4.7
125.7
EBITDA Growth (%) -19.00
SCLN's EBITDA Growth (%) is ranked higher than
53% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. SCLN: -19.00 )
SCLN' s 10-Year EBITDA Growth (%) Range
Min: -53.8   Max: 13.5
Current: -19

-53.8
13.5
EPS Growth (%) -22.50
SCLN's EPS Growth (%) is ranked higher than
57% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. SCLN: -22.50 )
SCLN' s 10-Year EPS Growth (%) Range
Min: -58.7   Max: 132.1
Current: -22.5

-58.7
132.1
» SCLN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SCLN Guru Trades in Q2 2013

Jim Simons 135,800 sh (+841.09%)
Chuck Royce 11,700 sh (unchged)
Paul Tudor Jones 25,800 sh (-59.56%)
» More
Q3 2013

SCLN Guru Trades in Q3 2013

Steven Cohen 22,664 sh (New)
Jim Simons 506,100 sh (+272.68%)
Chuck Royce 13,700 sh (+17.09%)
Paul Tudor Jones 28,100 sh (+8.91%)
» More
Q4 2013

SCLN Guru Trades in Q4 2013

John Burbank 13,513 sh (New)
Paul Tudor Jones 35,700 sh (+27.05%)
Chuck Royce 13,700 sh (unchged)
Steven Cohen Sold Out
Jim Simons 234,904 sh (-53.59%)
» More
Q1 2014

SCLN Guru Trades in Q1 2014

Jim Simons 263,007 sh (+11.96%)
Chuck Royce 15,100 sh (+10.22%)
Paul Tudor Jones Sold Out
John Burbank Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SCLN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2014-03-31 Sold Out $4.34 - $5.3 $ 5.3210%0
John Burbank 2013-12-31 New Buy$4.37 - $5.26 $ 5.3211%13513
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.70
SCLN's P/E(ttm) is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.50 vs. SCLN: 25.70 )
SCLN' s 10-Year P/E(ttm) Range
Min: 6.29   Max: 189.41
Current: 25.7

6.29
189.41
P/B 1.70
SCLN's P/B is ranked higher than
84% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. SCLN: 1.70 )
SCLN' s 10-Year P/B Range
Min: 0.82   Max: 6.15
Current: 1.7

0.82
6.15
P/S 2.30
SCLN's P/S is ranked higher than
78% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. SCLN: 2.30 )
SCLN' s 10-Year P/S Range
Min: 0.67   Max: 12.41
Current: 2.3

0.67
12.41
PFCF 130.20
SCLN's PFCF is ranked higher than
79% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCLN: 130.20 )
SCLN' s 10-Year PFCF Range
Min: 3.83   Max: 458
Current: 130.2

3.83
458
EV-to-EBIT 16.85
SCLN's EV-to-EBIT is ranked higher than
86% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. SCLN: 16.85 )
SCLN' s 10-Year EV-to-EBIT Range
Min: 0.2   Max: 207.3
Current: 16.85

0.2
207.3
Shiller P/E 18.30
SCLN's Shiller P/E is ranked higher than
92% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCLN: 18.30 )
SCLN' s 10-Year Shiller P/E Range
Min: 15.5   Max: 218.5
Current: 18.3

15.5
218.5
Current Ratio 5.79
SCLN's Current Ratio is ranked higher than
88% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. SCLN: 5.79 )
SCLN' s 10-Year Current Ratio Range
Min: 1.32   Max: 14.17
Current: 5.79

1.32
14.17
Quick Ratio 5.20
SCLN's Quick Ratio is ranked higher than
89% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. SCLN: 5.20 )
SCLN' s 10-Year Quick Ratio Range
Min: 1.05   Max: 14.17
Current: 5.2

1.05
14.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.30
SCLN's Price/Net Cash is ranked higher than
97% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCLN: 4.30 )
SCLN' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 343.8
Current: 4.3

2.06
343.8
Price/Net Current Asset Value 2.90
SCLN's Price/Net Current Asset Value is ranked higher than
98% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCLN: 2.90 )
SCLN' s 10-Year Price/Net Current Asset Value Range
Min: 1.19   Max: 225
Current: 2.9

1.19
225
Price/Tangible Book 2.40
SCLN's Price/Tangible Book is ranked higher than
83% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. SCLN: 2.40 )
SCLN' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 17.88
Current: 2.4

0.84
17.88
Price/DCF (Projected) 0.80
SCLN's Price/DCF (Projected) is ranked higher than
98% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCLN: 0.80 )
SCLN' s 10-Year Price/DCF (Projected) Range
Min: 0.69   Max: 6.05
Current: 0.8

0.69
6.05
Price/Median PS Value 1.00
SCLN's Price/Median PS Value is ranked higher than
85% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. SCLN: 1.00 )
SCLN' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 147.5
Current: 1

0.26
147.5
Price/Graham Number 1.70
SCLN's Price/Graham Number is ranked higher than
87% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SCLN: 1.70 )
SCLN' s 10-Year Price/Graham Number Range
Min: 0.68   Max: 4.95
Current: 1.7

0.68
4.95
Earnings Yield (Greenblatt) 5.70
SCLN's Earnings Yield (Greenblatt) is ranked higher than
78% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. SCLN: 5.70 )
SCLN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 482.2
Current: 5.7

0.5
482.2
Forward Rate of Return (Yacktman) 6.38
SCLN's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. SCLN: 6.38 )
SCLN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -20.8   Max: 8.8
Current: 6.38

-20.8
8.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:SPJ.Germany
SciClone Pharmaceuticals, Inc., a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. The Company's primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. It markets approximately 14 partnered products in China, including Depakine, a prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien in the US); and Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. It competitors for existing and future products include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company's products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.
» More Articles for SCLN

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: V, SCLN, VR, AMSG Jun 25 2012 
comment on SCLN Apr 29 2012 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-K/A) Dec 06 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2009 
SciClone Pharmaceuticals Inc. (SCLN) CEO Friedhelm Blobel buys 10,000 Shares May 26 2009 
SciClone Pharmaceuticals Inc. (SCLN) CFO Gary Titus buys 4,625 Shares May 26 2009 
Consumers Are Protected When Purchasing Service Contracts Dec 13 2008 

More From Other Websites
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 13 2014
Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target Jun 11 2014
SciClone to Present at Jefferies 2014 Global Healthcare Conference on June 3, 2014 May 27 2014
Nasdaq stocks posting largest percentage increases May 20 2014
SCICLONE PHARMACEUTICALS INC Financials May 20 2014
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q1 2014 Results - Earnings Call Transcript May 12 2014
SciClone Pharmaceuticals, Inc. Earnings Call scheduled for 8:30 am ET today May 12 2014
SciClone Pharmaceuticals (SCLN) Q4 2013 Results - Earnings Call Webcast May 12 2014
Q1 2014 SciClone Pharmaceuticals, Inc. Earnings Release - Before Market Open May 12 2014
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2014
SciClone reports Q1 adjusted EPS 10c, one estimate 8c May 12 2014
SciClone Reports Financial Results for the First Quarter 2014 May 12 2014
SciClone Pharmaceuticals to Report Financial Results for the First Quarter 2014 on May 12th May 05 2014
SciClone Pharmaceuticals Selects rfXcel to Meet China Product Compliance and Anti-Counterfeiting... Apr 23 2014
SciClone Pharmaceuticals Selects rfXcel to Meet China Product Compliance and Anti-Counterfeiting... Apr 23 2014
SciClone to Present at Needham Healthcare Conference on April 8, 2014 Apr 01 2014
Vista Partners Initiates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target Mar 18 2014
SCICLONE PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 17 2014
SciClone Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript Mar 12 2014
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 12 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide